EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost-effectiveness of antithrombotic therapies for peripheral arterial disease

Uday Dhanda, Dana Alameddine, Kurt S Schultz, Lydia Tran, David Silva, Martin D Slade, Loay Kabbani, Raul J Guzman, Ira L Leeds, Cassius Iyad Ochoa Chaar

Journal of Vascular Surgery · 2026-08 · 84 (2) · 448-458.e3

DOI: 10.1016/j.jvs.2026.03.629 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Vascular Surgery, 2026-08. Verfasst von Uday Dhanda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Drug Costs, Platelet Aggregation Inhibitors, Factor Xa Inhibitors. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Medtronic, Boston Scientific Corporation, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES Antithrombotic treatment plays a critical role in managing peripheral arterial disease and reducing the risk of major adverse limb events and major adverse cardiovascular events after revascularization. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is the most commonly used regimen following lower extremity revascularization (LER), but emerging studies suggest that dual antithrombotic pathway inhibition (DPI), which combines a factor Xa inhibitor with an antiplatelet agent, may offer enhanced protection. This study evaluates the clinical outcomes and cost-effectiveness of DPI compared with DAPT in patients undergoing LER. METHODS A retrospective analysis compared the characteristics of patients treated with DAPT and DPI after LER at Yale New Haven Hospital. After applying a 4:1 propensity score matching to adjust for differences in baseline characteristics, the outcomes of the two groups were compared. Cost-effectiveness was evaluated over a 5-year horizon using modeled costs and quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio was calculated. The willingness-to-pay (WTP) threshold was set at $150,000 per QALY, which aligns with the average U.S. WTP for health interventions. RESULTS A total of 986 patients undergoing LER were reviewed, with 5.6% on DPI. After propensity matching (N = 275), Kaplan-Meier analysis showed significantly improved major adverse limb event-free survival in the DPI group, with no difference in adverse cardiovascular event-free survival between the two groups. Although the DPI strategy incurred higher costs ($73,826 vs $39,548), it yielded greater health benefits (4.64 vs 3.51 QALYs). The incremental cost-effectiveness ratio was $30,331 per QALY, well below the U.S. WTP threshold of $150,000 per QALY, indicating that DPI is a cost-effective alternative compared with DAPT. CONCLUSIONS DPI is associated with improved limb-related outcomes and represents a cost-effective alternative to DAPT for antithrombotic therapy after LER.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Arterial DiseaseDrug CostsPlatelet Aggregation InhibitorsFactor Xa InhibitorsFibrinolytic AgentsDual Anti-Platelet TherapyHumansCost-Benefit AnalysisRetrospective StudiesFemaleMaleCost-Effectiveness AnalysisAgedQuality-Adjusted Life YearsTime FactorsTreatment OutcomeMiddle AgedRisk FactorsAged, 80 and overClopidogrelAspirin

Stichwörter der Autor:innen

Dual antithrombotic therapyMajor adverse limb eventsPeripheral artery disease

Substanzen

Platelet Aggregation InhibitorsFactor Xa InhibitorsFibrinolytic AgentsClopidogrelAspirin

Autor:innen und Institutionen

  • Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT.
  • Division of Vascular and Endovascular Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT.
  • Division of Colon and Rectal Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT.
  • Pharmacy Department, Yale New Haven Hospital, New Haven, CT.
  • Yale Occupational and Environmental Medicine Program, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
  • Division of Vascular Surgery, Department of Surgery, Henry Ford Hospital, Detroit, MI.

Förderung

  • Medtronic
  • Boston Scientific Corporation
  • National Institutes of Health

Zitieren

APA

Dhanda, U., Alameddine, D., Schultz, K. S., Tran, L., Silva, D., Slade, M. D., Kabbani, L., Guzman, R. J., Leeds, I. L., & Ochoa Chaar, C. I. (2026). Cost-effectiveness of antithrombotic therapies for peripheral arterial disease. Journal of Vascular Surgery, 84(2), 448-458.e3. https://doi.org/10.1016/j.jvs.2026.03.629

Vancouver

Dhanda U, Alameddine D, Schultz KS, Tran L, Silva D, Slade MD, et al. Cost-effectiveness of antithrombotic therapies for peripheral arterial disease. Journal of Vascular Surgery. 2026;84(2):448-458.e3. doi:10.1016/j.jvs.2026.03.629

BibTeX
@article{Dhanda2026,
  author = {Dhanda, Uday and Alameddine, Dana and Schultz, Kurt S and Tran, Lydia and Silva, David and Slade, Martin D and Kabbani, Loay and Guzman, Raul J and Leeds, Ira L and Ochoa Chaar, Cassius Iyad},
  title = {Cost-effectiveness of antithrombotic therapies for peripheral arterial disease},
  journal = {Journal of Vascular Surgery},
  year = {2026},
  volume = {84},
  number = {2},
  pages = {448--458.e3},
  doi = {10.1016/j.jvs.2026.03.629}
}
Kostenlos starten →